All In Biotech

NDA 216395 · Solubiomix

Quiofic

Folic Acid · Oral

Last checked: Nov 20, 2026Latest source record: Jan 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Jan 26, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,128

539 Phase 3, 261 recruiting

FAERS reports

250,981

186,221 serious, 23,615 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 5, 2026.

FOLIC ACID oral solution is indicated for the treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients. FOLIC ACID oral solution is a folate analog indicated for the treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients. ( 1 )

Mechanism: Folic acid acts on megaloblastic bone marrow to produce a normoblastic marrow. In man, an exogenous source of folate is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is the precursor of tetrahydrofolic acid, which is involved as a cofactor for transformylation reactions in the biosynthesis of purines and thymidylates of nucleic acids. Impairment of thymidylate synthesis in patients with folic acid deficiency is thought to account for the defective deoxyribonucleic acid (DNA) synthesis that leads to megaloblast formation and megaloblastic and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • QUIOFIC · FOLIC ACID 0.2MG/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Folic Acid" as an intervention, any sponsor and status, largest first.

All 2,128 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective25,501
  • fatigue24,215
  • pain23,889
  • arthralgia20,192
  • off label use18,427
  • rheumatoid arthritis18,093
  • nausea16,256
  • diarrhoea14,829
  • headache14,796
  • rash14,199
  • dyspnoea13,866
  • abdominal discomfort12,119

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044,028
20053,947
20063,047
20073,025
20083,897
20095,191
20105,881
20117,320
201210,346
201311,131
201411,991
201514,840
201616,506
201714,724
201815,635
201916,226
202018,152
202116,635
202216,696
202314,171
202414,802
202513,764
20269,022

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,613 on PubMed

Sponsor: Solubiomix

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.